Corporate News - Beijing Beilu Pharmaceutical Co., Ltd.

Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU

2025/04/11

Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regula...

VIEW_MORE

Reasonable Use of Iohexol Reasonable Use of Iohexol Adverse Reactions

2025/04/10

VIEW_MORE

Beilu Pharmaceutical Subsidiary Hichi Pharmaceutical's Iopamidol Approved for Market Release

2025/04/02

Recently, Hichi Pharmaceutical's iopamidol API received the "Approval Notice for the Marketing Application of Chemical APIs" from the National Medical Products Administration. This is an...

VIEW_MORE

Subsidiary Hichi Pharmaceutical's Iodixanol API Obtains Korean Registration Certificate

2025/03/28

Recently, Zhejiang Hichi Pharmaceutical Corporation Limited, a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received the product registration certificate for Iodixanol API issued by the Korea...

VIEW_MORE

Beilu Pharmaceutical and Chengqingtang Traditional Chinese Medicine Establish Strategic Cooperation

2025/02/24

Recently, Beijing Beilu Pharmaceutical Co., Ltd. and Anhui Chengqing Tang Traditional Chinese Medicine Co., Ltd. formally signed a strategic cooperation agreement in Bozhou, Anhui. The two parties wil...

VIEW_MORE

Beilu Pharmaceutical's Gadoterate Meglumine Injection Win the Bid for the 10th National Drug Centralized Procurement

2024/12/16

On December 12, 2024, Beilu Pharmaceutical participated in the bidding process for the 10th National Drug Centralized Procurement organized by the National Joint Drug Procurement Office. Beilu Pharmac...

VIEW_MORE

Beilu Pharma's Contrast Media Production Line Passed EU GMP Certification.

2024/11/14

Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Certificate Of GMP Compliance Of A Manufacturer" issued by the Dutch Medicines Evaluation Board in accordance with the relevant...

VIEW_MORE